Experimentally, HDAC inhibitor chidamide significantly inhibited the growth of EP300-mutated T-lymphoma cells and KMT2D-mutated T-lymphoma cells when combined with the hypomethylating agent decitabine [12]. The gene discussed is HDAC9; the disease is lymphoma.